Noveris Health Sciences Inc. (CSE:NVRS)
Canada · Delayed Price · Currency is CAD | Market Cap | 87.82M +28,341.9% |
| Revenue (ttm) | n/a |
| Net Income | 1.60M |
| EPS | 0.33 |
| Shares Out | 58.55M |
| PE Ratio | 4.58 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,063 |
| Open | 1.560 |
| Previous Close | 1.500 |
| Day's Range | 1.480 - 1.580 |
| 52-Week Range | 0.120 - 3.000 |
| Beta | -5.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Noveris Health Sciences
Noveris Health Sciences Inc., a biotechnology company, engages in developing and commercializing solutions for treating mental health problems and enhancing vitality. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Noveris Health Sciences Inc. was formerly known as Mydecine Innovations Group Inc. and changed its name to Nover... [Read more]
Financial Performance
Financial StatementsNews
Noveris Health Sciences Announces Appointment Of Nathan Mison As Chair Of Advisory Board
Vancouver, British Columbia – June 12, 2026 – TheNewswire – Noveris Health Sciences Inc. (“Noveris” or the “Company”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointment of Nat...
Noveris Health Sciences Appoints Geoff Griffiths As Strategic Advisor To Support Commercialization And Growth Initiatives
VANCOUVER, British Columbia, JUNE 8, 2026 - TheNewswire – Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) (“Noveris” or the “Company”) is pleased to announce the appointment of Geoff...
Noveris Health Sciences Provides Corporate Update
VANCOUVER, BC, Canada, June 5, 2026 – TheNewswire — Noveris Health Sciences Inc. (CSE: NVRS | FSE: 0NF0 | OTC: MYCOF) (“Noveris” or the “Company”) is pleased to provide this corporate update. Re-Eng...
Noveris Health Sciences Provides Corporate Update, and Announces Agreement for Acquisition of Stem Cell Distribution Business
Vancouver, British Columbia – TheNewswire - April 29, 2026 – Noveris Health Sciences Inc. (the “ Company ”, or “ Noveris ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) wishes to provide a corporate update. N...
Noveris Health Sciences Inc. Announces Signing Of Market Making Advisory Agreement With DS Market Solutions Inc.
Vancouver, British Columbia, April 22, 2026 - TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has entered into an advis...
Noveris Health Sciences Inc. Provides Clarifying News Release Regarding Life Offering And Other Disclosure
Vancouver, British Columbia, April 20, 2026 – TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that, as a result of a review by the British C...
Noveris Provides Announces Trading Halt Order, And Clarification As To Article
Vancouver, British Columbia, March 26, 2026 – TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that the British Columbia Securities Commissio...
Noveris Announces Closing of Life Offering
Vancouver, British Columbia – TheNewswire - March 18, 2026 – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has completed its previo...
Noveris Health Sciences Inc. Unaware Of Any Material Change
Vancouver, British Columbia, March 16, 2026 – TheNewswire - At the request of CIRO, Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) wishes to confirm that the Compa...
Noveris Health Sciences Launches Investor Website and Engages Fairfax Partners Inc. for Investor Relations and Digital Marketing Services
VANCOUVER, BC – TheNewswire - March 13, 202 6 – Noveris Health Sciences Inc. ( CSE: NVRS) ( FSE: 0NF0) ( OTC: MYCOF) (the " Company ") is pleased to announce the launch of its new investor-facing w...
Noveris Announces Resignation Of CEO
Vancouver, British Columbia, March 10, 2026 – TheNewswire — Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that Joshua Bartch has resigned as direc...
Noveris Announces Conversion Of Debentures; Filing Of Early Warning Reports By JJK Holdings Ltd. And Joshua Bartch
Vancouver, British Columbia, March 6, 2026 — TheNewswire - Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today the conversion of debentures in the aggre...
JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd.
Vancouver, British Columbia, February 27, 2026 - TheNewswire — Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that JJK Holdings Ltd. (“ JJK ”) acqu...
Noveris Provides Supplemental Disclosure Regarding Previously Announced Convertible Debenture Issuances
Vancouver, British Columbia, February 18, 2026 — TheNewswire - Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that it is providing additional disclosure ...
CSE Bulletin: Name and Symbol Change - Mydecine Innovations Group Inc. (MYCO)
Toronto, Ontario--(Newsfile Corp. - Le 2 février/February 2026) - Mydecine Innovations Group Inc. (MYCO) has announced a name and symbol change to Noveris Health Sciences Inc. (NVRS). Shares will begi...
CSE Bulletin: Consolidation - Mydecine Innovations Group Inc. (MYCO)
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Mydecine Innovations Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post...
Mydecine Innovations Group Closes Debt Settlements
Vancouver, British Columbia, October 14, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has closed the previou...
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology comp...
Mydecine Innovations Group Announces Director Resignation
VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology c...
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology co...
Mydecine Announces Update Regarding the Special Access Program
DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovativ...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engin...
Mydecine Provides Q4 2023 Business Update
VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engi...
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the n...
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the ...